First patient accrued on 20 September 2013!
NEW! First patients with colorectal cancer enrolled in the EORTC SPECTAcolor Biobanking Project
A new approach in treating patients with advanced colorectal cancer: Biomarker based personalized medicine advances to benefit cancer patients!
A Biobank purely dedicated to colorectal cancer: Where colorectal cancer facts and figures speak for themselves…
Colorectal cancer (CRC) – Cancer of the colon and rectum is the second most frequent malignant disease in Europe and the third most common cancer worldwide. air max 1 femme It has been estimated that 446,800 citizens in Europe are newly diagnosed every year and approximately 214.700 of them will die each year. hogan scarpes shop When in advanced stages, the average life expectancy beyond diagnosis for fatal cases is estimated between 2 to 3 years. This calls for urgent research.
Further to the announcement of the partnership started in September 2011, Alliance Boots and the EORTC Charitable Trust are now pleased to announce that following the successful completion of the preliminary operational, legal and financial phases of the SPECTAcolor Biobank project, the Screening Platform for Clinical Trials in Advanced Colorectal Cancer (SPECTAcolor) is now operational and has enrolled its first 11 patients!
Prof. Nike Air Max 2017 Dames zwart nike goedkoop Sabine Tejpar in Leuven, Belgium co-Coordinator of this project adds, “SPECTAcolor will facilitate the transformation of experimental discoveries into new treatments, have a significant clinical impact, and provide feedback from the clinic to the bench. It should be seen as a constantly evolving system with the ability to support new trials with innovative treatments.”
The first 10 patients have enrolled in the Dresden Clinical centre in Germany whereas the 11th one is enrolled in the Clinical centre of Geneva, Switzerland. new balance 998 homme
SPECTAcolor in brief,
SPECTAcolor is the first ever tumour tissue samples biobank and biomarker analysis platform for genetic profiling of patients suffering from advanced colorectal cancer.
This platform, unique of its kind joins up research clinical forces at a Pan-European level to develop personalized treatments based on the results of the tissue sampling analysis.
Supported by a network of 25 clinical centres in 10 countries, this initiative has the ultimate goal of enabling better access to new treatment options. air max pas cher billig nike air max 2016 Between 600 and 1000 patients with advanced colorectal cancer are expected to enroll each year.
The SPECTAcolor platform will test molecular alterations in colorectal cancer patients whose disease is spreading fast. Nike Air Max 2017 Dames roze These patients are then tested to identify their specific cancer markers to offer the possibility to enter them into biomarker -led clinical trials .
Adult patients with pathologically confirmed metastatic colorectal cancer are invited to give their informed consent to test for mutations in colorectal cancer biomarkers. adidas 2017 pas cher kanken fjallraven france In addition, further other specific cancer genes will be tested using most advanced genetic research technologies to identify deeper alterations that may intrinsically drive cancer cells.
Moreover, the SPECTAcolor Biobank plays a vital role in making advances in personalized medicine as the discoveries based on the analysis of the biomarkers will enable to develop targeted therapies to meet the needs of each individual colorectal cancer patient bringing therefore hope for a cure.
SPECTAcolor is supported by EORTC Charitable Trust and the corporate social responsibility program of Alliance Boots. Soldes Under Armour The EORTC recognizes the European Society of Pathology and the Sanger Institute for their active and high quality contributions.
This unique partnership between the EORTC Charitable Trust and AB makes it possible.